EXPERIMENTAL STUDY

Mesenchymal stem cell condition medium enhanced cell viability in morphine-treated cells

Zhaleh H1, Bidmeshki Pour A2, Azadbakht M2

Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. hossain_jale@yahoo.com

ABSTRACT

Bone marrow mesenchymal stem cells (BM-MSC) have recently been predicted to have a major therapeutic potential due to secretion of soluble factors and the release of cytokines and growth factors, which could mediate the cellular communication to induce cell differentiation/maturity.

The aim of the present study was to determine the effect of mBM condition medium on morphine-induced cell death in PC12, U87, AGS and MCF-7 cell lines. The condition media were harvested as mBM soup (mBM soup 24 and mBM soup 48h, respectively). To investigate the effect of mBM soup on cell lines, morphological changes were studied with an inverted microscope, the viability of cells was determined with trypan blue staining and MTT assay, the type of cell death was determined using Hoescht / PI staining, and NO secretion analysis. Viability assay showed that mBM soup (24 and 48 h) in time-dependent manner increased cell viability (p<0.05) and cell death assay showed that cell death decreased in a time-dependent manner (p<0.05). Our findings suggest that mBM soup can enhance the proliferation and growth of cell lines and can suppress cell death induced by morphine (Fig. 8, Ref. 59).

Key words: morphine, BM-MSC soup, cell viability, cell death, NO.

Introduction

Morphine as an analgesic drug can induce apoptosis in proliferating cells (1–4), immunocytes (5, 6), cancer cells (7, 8), neuroblastsoma cells such as: SK-N-SH, NG108-15 and PC12 cells (9–11), and neuronal cells (12, 13), as well as human microglia (14) and inhibit growth of PC-9, HL-60 and KATO III cancer cell or cancer lines (15). On the other hand, it has been showed that morphine could induce apoptosis in non-cancerous cells such as: endothelial cells (16), T lymphocytes, macrophages (17), microglia and neurons derived from rat brain (18).

On the other hand, previous studies on the amazing neuro-differential potential of MSCs attracts an intense interest in the possible applications of MSCs in cell and gene therapy for neurological disease, because MSCs can be obtained from bone marrow easily and expanded rapidly in vitro (19, 20).

On the other side, the most recent mechanism of action of BMSC cells is a local paracrine effect (21, 22). It has been showed that transplanted MSCs had the ability to produce growth factors (23–25). In summary, tissue regeneration and improvements have been proposed as paracrine effect of stem cell action (26, 27). However, MSCs can secrete a variety of bioactive molecules such as: trophic factors and anti-apoptotic molecules, which may provide the main mechanism responsible for their therapeutic effect (28).

Meanwhile, these factors are cytokines; growth factor and other factors induce cytoprotection, neovascularization, and medium endogenous tissue regeneration via activation of resident tissue stem cells. In addition, tissue remodeling and organ function are affected by these paracrine factors (22).

However, how they survive and differentiate into distinct cell types is still not clear. The aim of this study was to determine the effect of mBM condition medium on morphine-induced cell death in different cell lines.

Material and methods

Preparation of mouse bone marrow cells

Isolation and culture of mBMSCs were carried out as previously described method (29). Bone marrow was obtained from 6–8-week-old NMRI mice. Cell suspension was incubated at 37 °C in humidified atmosphere containing 5 % CO₂ for 72 hours. After that, the nonadherent cells were removed by replacing the medium. Culture medium was replaced every 2 or 3 days about 2 weeks. When cell cultures reached to 70% confluence, they were harvested with trypsin-EDTA 0.25 % (Sigma) for 5 minutes, again cultured to next confluence and harvested. Expanded cells from passages five-eight were used for further testing.

The surface marker expression of mBMSC cells was assessed by a flow cytometry. 1×10⁶ cells/ml mBMSC were suspended and stained with FITC- or R-phycocerythrin (PE)-conjugated monoclonal antibodies, such as: CD14 (eBioscience), CD105 (eBio-
science), CD73 (eBioscience), CD29 (Biolegend), CD34 (Santa Cruz), CD45 (eBioscience), CD90 (Biolegend).

**mBM condition medium**

Briefly, after confirming and harvesting the mBMSC cells, cells were cultured in DMEM: F12 culture medium, when cell reached to 80 % confluence, the media were changed by fresh DMEM: F12 supplemented with 0.2 % BSA culture medium. The cells maintained for 24 h or 48 h. Then, the condition media were harvested as mBM soup 24 and mBM soup 48 h, respectively. Protein concentration of mBM Soup was 0.52 μg/ul (from 10⁶ cells).

**Cell lines**

PC12, U87, MCF-7 and AGS cells were grown in a 25-cm² tissue culture flask in DMEM culture media (Gibco), supplemented with 5 % fetal bovine serum (FBS, Gibco; UK), 100 u/ml of penicillin (Sigma) and 100 mg/ml streptomycin (Sigma). The cells were maintained in standard condition (37 °C and 5 % CO₂).

**Cell treatment**

One day after plating the different cell lines in DMEM culture media containing 0.2 % BSA, cells were washed with PBS, pH 7.4. There were six treatments including; treatment 1: 1mM morphine, treatment 2: culture medium, treatment 3: mBM Soup 24 h, treatment 4: mBM Soup 24 h together with 1 mM morphine, treatment 5: mBM Soup 48 h and treatment 6: mBM Soup 48 h together with 1mM morphine.

**Cell viability measurement**

Trypan blue viability measurement was performed by standard methods (30).

The traditional method of performing trypan blue (0.4gr / 100ml in PBS) cell viability analysis involves a manual staining and a use of hemocytometer for counting.

**Cell proliferation assay**

To perform the test, 1×10⁴ different cell lines were loaded into 96-well plate and 200 μL of DMEM: F12 medium containing 0.2 % BSA was added. After 24-hour incubation, 200 μL of different treatment media as described was added to the wells. The cells were separately incubated with different treatments medium for 24 and 48 hours. Cell proliferation was quantified by MTT assay. MTT cytotoxicity measurement was performed by standard methods (31). The optical density of each well was measured using a plate reader at 570 and 630 nm.

**Quantification of cell death incidence**

Hoechst/PI nuclear staining was carried out as previously described (32). Briefly, cells were plated in 24 well culture plates with 5×10⁴ cells/well density for 24 h. Cells were treated with different treatment media for a

---

**Figure 1.** Cell viability assessed by trypan blue after exposed to different treatment media. T1: 1 mM morphine, T2: control cells, T3: mBM Soup 24 h, T4: mBM Soup 24 h together with 1 mM morphine, T5: mBM Soup 48 h and T6: mBM Soup 48 h together with 1mM morphine. All data represented by mean ± standard. * p < 0.05 as evaluated by paired ANOVA.
range of times (6, 12, 24 and 48 h). Then cells were incubated for 30 min at 37 °C with Hoechst 33342 dye (10 ng/ml in PBS), washed twice in PBS. PI (50 ng/ml in PBS) was added just before microscopy. Cells were visualized using an inverted fluorescence microscope (Olympus IX-71, Japan). The apoptotic index was calculated by the fraction of numbers of apoptotic cells on the total cell count in 100 (300 cells), respectively.

**NO assay**

NO was measured using the Griess staining method (33). All wells were incubated for 15 minutes and were assessed using a plate Reader at wavelengths of 570 and 630 nm.

---

**Results**

**Characteristics of BMSCs**

The cells as mBMSCs were derived from female and male NMRI mice. The 5th passage of cells had similar morphology. The results showed that about 98 % cells of mBMSCs were CD90-positive and a lack of expression of CD14, CD45 and CD34. These results showed that mouse Bone marrow cells had the characteristics of mesenchymal stem cells, which were carried out as previously described (our published manuscript DOI: 2016, 5, 11:22-33, IJMRHS).

---

![Fig. 2. Cell proliferation (%) assessed by MTT in different treatment media and different culture periods.](image1)

Fig. 2. Cell proliferation (%) assessed by MTT in different treatment media and different culture periods. T1: 1 mM morphine, T2: control cells, T3: mBM Soup 24 h, T4: mBM Soup 24 h together with 1 mM morphine, T5: mBM Soup 48 h and T6: mBM Soup 48 h together with 1 mM morphine. All data represented by mean ± standard. * p < 0.05 as evaluated by paired ANOVA.

![Fig. 3. Nitric oxide (NO) levels in different treatments and different culture periods.](image2)

Fig. 3. Nitric oxide (NO) levels in different treatments and different culture periods. T1: 1 mM morphine, T2: control cells, T3: mBM Soup 24 h, T4: mBM Soup 24 h together with 1 mM morphine, T5: mBM Soup 48 h and T6: mBM Soup 48 h together with 1 mM morphine. All data represented by mean ± standard. * p < 0.05 as evaluated by paired ANOVA.
Cell viability and cell proliferation

Comparison of the mean PC12, U87, MCF-7 and AGS cell viabilities using the trypan blue method after 6, 12, 24 and 48 hours indicated a significant difference between the treatments \( (p<0.05) \). After 6, 12, 24 and 48 hours the percentage of cell viability in treatments 1, 4 and 6 were decreased compared to the treatment 2 \( (97\%) \) \( (p<0.05) \). After 6, 12, 24 and 48 hours, the percentages of cell viability were not different in treatments 3 and 5 compared to treatment 2. The percentage of cell viability was increased in treatment 3 compared to the treatment 4 \( (p<0.001) \) (Fig. 1). The percentage of cell viability was increased in treatments 4 and 6 compared to the treatment 1 \( (p<0.05) \). Comparison of the mean cell proliferation analyzed using the MTT assay after 24 and 48 hours revealed a significant increase between the treatments compared to the treatment 1, respectively \( (p<0.05) \). Cell proliferation was again significantly decreased by increasing the time in treatment 1 compared to the treatment 2 \( (p<0.05) \). The cell proliferation was increased in treatments 4 and 6 compared to the treatment 1 \( (p<0.05) \). The percentage of cell proliferation was lowest in the treatment 1 and was highest in the treatments 3 and 5 \( (p<0.05) \) (Fig. 2).

NO levels

NO concentration was evaluated using the Griess method. The effect of different concentrations of staurospurine on PC12, U87, MCF-7 and AGS cells after 24 and 48 hours indicated a time-dependent decrease in NO secretion compared to the control treatment, respectively \( (p<0.05) \).

Figure 4 shows NO concentration amounts \((\mu M)\) in the culture medium of PC12, U87, MCF-7 and AGS cells that contained staurospurine \((1\, \mu M)\) plus different mBM soup for 24 and 48 incubation times. After 24 and 48 h incubation, the NO concentration in treatment 1 was decreased in the medium compared to the control sample (treatment 2), respectively \( (p<0.05) \). After the 24 and 48 h incubation, NO concentration significantly increased, when cells were treated with treatments 2–6 compared to the treatment 1 \( (p<0.05) \). Data showed that the highest NO concentration was in the treatment 6 and the lowest concentration was in the treatment 1 in culture medium for 24 and 48 h, respectively \( (p<0.05) \) (Fig. 3).

Cell death indexes

The cell death index of PC12, U87, MCF-7 and AGS cells treated with different treatments showed an increase from the treatment 1 to other treatments in order of the time, respectively \( (p<0.05) \). After 6, 12, 24 and 48 h, the cell death index was highest in the treatment 1 and lowest in the treatments 3 and 5,
respectively (p<0.05). The cell death index was increased in the treatment 1 compared to the treatment 2, respectively (p<0.05). The cell death index of PC12, U87, MCF-7 and AGS cells in treatment 4 was increased compared to the treatment 3 (p<0.05). The cell death index of cells in the treatment 6 was increased compared to the treatment 5 (p<0.05). The cell death index of PC12, U87, MCF-7 and AGS cells were decreased in the treatments 2, 3 and 5 compared to the treatment 1 after 6–48 h incubation, respectively (p<0.05) (Fig. 4). Morphology of PC12 (Fig. 5), U87 (Fig. 6), MCF-7 (Fig. 7) and AGS (Fig. 8) were examined by a fluorescence microscopy.

Discussion

Morphine as an opioid drug exerts a variety of biological effects, which may be mediated through mechanisms other than the classic opioidergic receptors. The exact mechanism whereby morphine modulates cell survival and cell death is not clearly understood (34).

Cell viability was measured by MTT assay. On the other hand, apoptosis was detected by Hoechst/Propidium Iodide staining test (specific test for apoptosis) and NO secretion.

In the first step of the present study, PC12, U87, AGS and MCF-7 cancer cell lines were exposed to 1mM concentration of morphine as an apoptotic dose. The proapoptotic and necrotic effects of morphine were shown in multiple cell lines (35–39). In agreement with the other investigations, the results of Trypan blue, MTT assay and Hoechst/Propidium Iodide staining test showed that morphine decreased the cell viability and increased the number of apoptotic cells, respectively (37, 38). In the second part of this investigation, the protective effect of mBM Soup was investigated. There are not any common grounds for the interaction between mBM soup and morphine. Here, for the first time, we showed that administrations of mBM Soup were effective for a suppression of morphine-induced cell death in neuronal (PC12), glioblastoma (U87), gastric cancer (AGS) and Breast cancer (MCF-7) cells. Our data showed that application of mouse adult bone marrow stromal cells (BMSC) Soup treatment is mediated by enhanced trophic support of the cancer cells. Another study demonstrated that MAPK activation provided cells with type-specific signals important for cellular differentiation, proliferation, and survival. MAPK activation is an important survival signal in the neurons and may mediate the pro-survival effects for cAMP in neuronal and neuroglial...
cells (40). The previous study showed that MSC could express a number of glial cell markers such as: S100 and GFAP and that these cells promoted neurite outgrowth (41). It has been shown that MSC significantly enhanced neurite outgrowth of DRG neurons. Data showed that mRNA transcripts for NGF, GDNF, NT3, BDNF, TGFβ and VEGF were expressed in undifferentiated MSC (42). This result is consistent with another study in rat MSC (43). It showed that BDNF levels correlated with the enhancement of SH-SY5Y (44) and DRG (45) neurite outgrowth in response to MSC. Meanwhile, Tyrosine kinase receptor signaling by MSC soup can induce MAPK activation and increase cell viability and cell proliferation and decrease cell death in the cells.

Meanwhile, Tyrosine kinase receptor signaling activation like TGF-β or NGF by BM-MSC soup can induce MAPK activation and increase cell viability and cell proliferation and decrease cell death in the cells. It is confirmed by a recent study. It was shown that Condition Medium from MSCs, particularly from genetically modified MSCs overexpressing Akt-1 (Akt-MSCs), exerted cardiomyocyte protection (46). It has been showed that injected MSCs acted via a paracrine mechanism and secreted trophic factors, which enhance angiogenesis, synaptogenesis, and neurogenesis (47). Meanwhile, MSC secretes trophic factors that inhibit scar formation (mainly caused by astrocytosis) as well as stimulate neural progenitor cells (NPCs) proliferation, migration and differentiation (48, 49). Hung, et al (2007) showed that conditioned medium of BM-MSCs can activate the PI3K/Akt pathway in hypoxic endothelial cells resulting in an inhibition of apoptosis, and increased cell survival, and stimulation of angiogenesis. Data showed that BM-MSC Soup had a higher content of anti-apoptotic and angiogenic factors, such as: IL-6, VEGF, and monocyte chemotactrant protein (MCP)-1 (50).

However, opposing results were documented. For example, in PC3 cells (an animal model of prostate cancer) MSCs promote fibroblast growth factor 2 (FGF2) secretions. It has been shown that MSCs promoted tumor angiogenesis by enhancing the expression of endothelin-1 in colon cancer cell lines (50, 51). It has been shown that co-culturing gastric cancer cell lines with MSCs increased the proportion of CD133-positive gastric cancer cells (52, 53). It has been showed that TGF-β expression in MSCs promoted tumor growth of prostate cancer cell lines in mice. This tumor growth-promoting effect of MSCs can be blocked by siRNAs against TGF-β (54). Cell survival factor inhibits
cell apoptosis through activating specific signaling pathway(s), including the PI3K/Akt pathway. It has been shown that transfection of constitutively active Akt prevented cell apoptosis, while a dominant-negative Akt induced cell apoptosis (55). In the other side, recent studies showed that inhibitors of the PI3K/Akt pathway could sensitize cells to apoptotic stimuli (56, 57). For example, Osaki et al, showed that inhibition of PI3K caused an inhibition of cell proliferation without induction of cell apoptosis and that inhibition of the PI3K-Akt signaling pathway significantly increased the sensitivity of cell apoptosis (58).

The present study might suggest new strategies for the treatment and enhancement of cell proliferation and suppression of opioids induced cell death, using mBM soup as anti-apoptosis or necrosis inducer.

References

1. Hatsukari I, Hitosugi N, Ohno R, Hashimoto K, Nakamura S, Satoh K. Induction of cell death by morphine in human tumor cell lines in vitro. Anticancer Res 2007; 27: 857–864.
2. Gutstein HB, Akil H. Opioid analgesic. In: Brunton LL, Lazo JS, Parker KL. Goodman and Gilman’s, The Pharmacological Basis of Therapeutic. 11thed. New York: McGraw-Hill: 2006: 547–590.
3. Tegeder I, Geisslinger G. Opioids as modulators of cell death and survival unraveling mechanisms and revealing new indications. Pharmacol Rev 2004; 56: 351–369.
4. Mao J, Sung B, Ji RR, Lim G. Neuronal apoptosis associated with morphine tolerance: evidence for an opioid-induced neurotoxic mechanism. J Neurosci 2002; 22: 7650–7661.
5. Singhal PC, Reddy K, Franki N, Sanwal V, Gibbons M. Morphine induces splenocyte apoptosis and enhanced mRNA expression of cathepsin-B. Inflammation 1997; 21: 609–617.
6. Singhal PC, Sharma P, Kapasi AA, Reddy K, Franki N, Gibbons M. Morphine enhances macrophage apoptosis. J Immunol 1998; 160: 1886–1893.
7. Hatzoglou A, Bakogeorgou E, Castanas E. The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. Eur J Pharmacol 1996; 296: 199–207.
8. Tegeder I, Grosch S, Schmidtto K, Haussler A, Schmidt H, Niederberger E, Scholich K, Geisslinger G. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res 2003; 63: 1846–1852.
9. Yin DL, Ren XH, Zheng ZL, Pu L, Jiang LZ, Ma L, Pei G. Etopophine inhibits cell growth and induces apoptosis in SK-N-SH cells: involvement of pertussis toxin-sensitive G proteins. Neurosci Res 1997; 29: 121–127.
10. Kugawa F, Arae K, Ueno A, Aoki M. Buprenorphine hydrochloride induces apoptosis in NG108-15 nerve cells. Eur J Pharmacol 1998; 347: 105–112.
11. Oliveira MT, Rego AC, Macedo TR, Oliveira CR. Drugs of abuse induce apoptotic features in PC12 cells. Ann NY Acad Sci 2003; 1010: 667–670.
12. Boronat MA, Garcia-Fuster MJ, Garcia-Sevilla JA. Chronic morphine induces up-regulation of the pro-apoptotic Fas receptor and down-regulation of the anti-apoptotic Bcl-2 oncprotein in rat brain. Br J Pharmacol 2001; 134: 1263–1270.
13. Mao J, Sung B, Ji RR, Lim G. Neuronal apoptosis associated with morphine tolerance: evidence for an opioid-induced neurotoxic mechanism. J Neurosci 2002; 22: 7650–7661.
14. Hu S, Sheng WS, Lokensgard JR, Peterson PK. Morphine induces apoptosis of human microglia and neurons. Neuropharmacology 2002; 42: 829–836.
15. Sueoka N, Sueoka E, Okabe S. Anti-cancer effects of morphine through inhibition of tumour necrosis factor-a release and mRNA expression. Carcinogenesis 1996; 17: 2337–2341.
16. Hsiao PN, Chang MC, Cheng WF, Chen CA, Lin HW, Hsieh CY, Sun WZ. Morphine induces apoptosis of human endothelial cells through nitric oxide and reactive oxygen species pathways. Toxicology 2009; 256: 83–91.
17. Kapasi AA, Coscia SA, Pandya MP, Singhal PC. Morphine modulates HIV-1 gp160-induced murine macrophage and human monocyte apoptosis by disparate ways. J Neuroimmunol 2004; 148: 86–96.
18. Hu S, Sheng WS, Lokensgard JR, Peterson PK. Morphine induces apoptosis of human microglia and neurons. Neuropharmacology 2002; 42: 829–836.
19. Colter DC, Class R, DiGirolamo CM, Prockop DJ. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci USA 2000; 97: 3213–3218.
20. Javazon EH, Colter DC, Schwarz EJ, Prockop DJ. Rat marrow stromal cells are more sensitive to plating density and expand more rapidly from single-cellderived colonies than human marrow stromal cells. Stem Cells 2001; 19: 219–225.
21. Tyndall A, Gratwohl A. Adult stem cell transplantation in autoimmune disease. Curr Opin Hematol 2009; 16: 285–291.
22. Gneecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008; 103: 1204–1219.
23. Parr AM, Tator CH, Keating A. Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplant 2007; 40: 609–619.
24. Chopp M, Li Y. Treatment of neural injury with marrow stromal cells. Lancet Neurol 2002; 1: 92–100.
25. Si YL, Zhao YL, Hao HJ, Fu XB, Han WD. MSCs: Biological characteristics, clinical applications and their outstanding concerns. Aging Res Rev 2011; 10:93–103.
26. Prockop DJ. Repair of tissues by adult stem/progenitor cells MSCs: controversies, myths, and changing paradigms. Mol Ther 2009; 17: 939–946.
27. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/ multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current views. Stem Cells 2007; 25: 2896–2902.
28. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytkine Growth Factor Rev 2009; 20: 419–427.
29. Nadri S, Soleimani M, Hosseni RH, Massumi A, Atashi A, Izadpanah R. An efficient method for isolation of murine bone marrow mesenchymal stem cells. Int J Dev Biol 2007; 51: 723–729.
30. Patel S, GheeWala N, Suthar A, Shah A. In vitro cytotoxicity activity of solanum nigrum extract against Hela cell line and vero cell line. Pharmaceut Sci 2007; 1: 297–307.
31. Ghosh K, Chandra K, Ojha AK, Sarkar S, Islam SS. Structural identification and cytotoxic activity of a polysaccharide from the fruits of Lagenaria siceraria. Laur Carbohydr Res 2009; 344: 693–698.
32. Yuan W, Guo J, Li X, Zou Z, Chen G, Sun J, Wang T, Lu D. Hydrogen peroxide induces the activation of the phospholipase C-g1 survival pathway in PC12 cells: protective role in apoptosis. Acta Biochem Biophys Sin Shanghai 2009; 41: 625–30.

33. Miranda KM, Espesy MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001; 5: 62–71.

34. Tegeder I, Geisslinger G. Opioids as modulators of cell death and survival—unraveling mechanisms and revealing new indications. Pharmacol Rev 2004; 56: 351–369.

35. Yoshida A, Tokuyama S, Iwamura T, Ueda H. Opioid analgesic-induced apoptosis and caspase-independent cell death in human lung carcinoma A549 cells. Int J Mol Med 2000; 6: 329–335.

36. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D. Apoptosis of NG108-5 cells induced by morphine in human tumor cell lines in vitro. Anticancer Res. 27: 857–864.

37. Hatsukari I, Hitosugi N, Ohno R, Hashimoto K, Nakamura S, Satoh K. 2007. Induction of apoptosis by morphine in human tumor cell lines in vitro. Anticancer Res. 27: 857–864.

38. Diao CT, Li L, Lau SY, Wong TM, Wong NS. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002; 62: 4491–4498.

39. Kugawa F, Ueno A, Aoki M. Morphine suppresses lymphocyte apoptosis by blocking p53-mediated death signaling. Biochem Biophys Acta 2000; 1499: 49–62.

40. Dugan LL, Kim JS, Zhang Y, Bart RD, Sun Y, Holtzman, DM, Girton HM. Treatment of neural injury with marrow stromal cells. Nat Med 2005; 11: 367–368.

41. Kern S, Eichler H, Stoewe J, Kluter H, Bieback K. Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood or Adipose Tissue. Stem Cells 2006; 45: 673–699.

42. Tsai CC, Chen YJ, Yew TL, Chen LL, Wang JY. Hypoxia inhibits its senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 2011; 117: 459–469.

43. Oskowitcz A, McFerrin H, Gutschow M, Carter ML, Pochampally R. Serum-deprived human multipotent mesenchymal stromal cells MSCs are highly angiogenic. Stem Cell 2011; 6: 215–225.

44. Gneecci M, He H, Noisex N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005; 11: 367–368.

45. Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 2012; 10: 244–258.

46. Gneecci M, He H, Noisex N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, Dzau VJ. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediumted cardiac protection and functional improvement. FASEB J 2006; 20: 661–669.

47. Chopp M, Li Y. Treatment of neural injury with marrow stromal cells. Lancet Neurol 2002; 1: 92–100.

48. Chen J, Li Y, Katakowski M, Chen X, Wang L. Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J Neurosci Res 2003; 73: 778–786.

49. Bai L, Caplan A, Lennon D, Miller RH. Human mesenchymal stem cells signals regulate neural stem cell fate. Neurochem Res 2007; 32: 353–362.

50. Hung SC, Pochampally RR, Chen SC, Hsu SC, Prockop DJ. Antiangiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 2007; 25: 2363–2370.

51. Huang WH, Chang MC, Tsai KS, Hung MC, Chen HL, Hung SC. Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene 2013; 32: 4343–4354.

52. Lin G, Yang R, Banie L, Wang G, Ning H, Li LC. Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. Prostate 2010; 70: 1066–1073.

53. Li Z. CD133: a stem cell biomarker and beyond. Exp Hematol Oncol 2013; 2: 17–24.

54. Nishimura K, Sembra S, Aoyagi K, Sasaki H, Yokozaki H. Mesenchymal stem cells promote an advantageous tumor microenvironment for the restoration of cancer stem cells. Pathobiology 2012; 79: 290–306.

55. Cheng J, Li L, Liu Y, Wang Z, Zhu X, Bai X. Interleukin-1alpha induces immunosuppression by mesenchymal stem cells promoting the growth of prostate cancer cells. Mol Med Rep 2012; 6: 955–960.

56. Suzuki S, Chuang LF, Doi RH, Chuang RV. Morphine suppresses lymphocyte apoptosis by blocking p53-mediumted death signaling. Biochem Biophys Res Commun 2003; 308: 802–808.

57. Fahy BN, Schlieman M, Virudachalam S, Bold RJ. Akt inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Brit J Cancer 2003; 89: 391–397.

58. Osaki M, Kase S, Adachi K, Takeda A, Hashimoto K, Ito H. Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediumted apoptosis in human gastric carcinoma cell line, MKN-45. J Cancer Res Clin Oncol 2004; 130: 8–14.

59. Nicola BI, Hea SL, Landshamer S, Straube A, Padovan CS, Plewnia N, Culmsee C. Bone marrow stromal cells mediumted protection through stimulation of PI3-K/Akt and MAPK signaling in neurons. Neuint 2006; 8: 213–221.

Received December 7, 2019. Accepted January 28, 2020.